We will first discover, design and characterise small molecules for candidate therapeutics to treat viral, bacterial, fungal and parasitic agents.

We will utilize facilities housed across the Centre, including at the Institute for Molecular Bioscience and the Australian Institute for Bioengineering and Nanotechnology.

We will further utilise research strengths of AID members in protein structural biology (NMR and X-Ray structures).

We will consolidate assay development, screening, compound libraries, chemoinformatics, modelling, synthetic and medicinal chemistry capacity into one location for application against infectious disease agents.  

We then will have the opportunity to use our capacity to move into pre-clinical and clinical studies at the QIMR Berghofer Medical Research Institute/Herston site.